Taken together, these results strongly suggest that the circulating FGF21 level may reflect the severity of hepatic steatosis and may indicate the early onset of NAFLD progression, thus representing a candidate biomarker of metabolic disorders [12,180]. This evidence concerns the gene FGF21 and Hepatic steatosis.